Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-73.0% vs price
Base Case (Median)
-61.6% vs price
Bull Case (75th pct.)
-43.7% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $16.66 | -57.9% | High (40%) |
| PE Comparable | $13.70 | -65.3% | Medium (25%) |
| Graham Number | $9.65 | -75.6% | Medium (40%) |
| EV/EBITDA | $28.02 | -29.1% | Medium (20%) |
| EV/FCF | $24.14 | -38.9% | Medium (20%) |
| Earnings Power Value | $4.69 | -88.1% | Medium (50%) |
Based on 6 out of 7 methods, TEVA appears overvalued at the current price of $39.53. The base case fair value of $15.18 implies 61.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.